Trial Profile
An Open-label Phase II Trial of Erlotinib and Bevacizumab in Patients With Advanced Non-small Cell Lung Cancer and Activating EGFR Mutations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Aug 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Acronyms BELIEF
- 05 Dec 2019 Results published in the Journal of Thoracic Oncology.
- 02 Nov 2018 Status changed from active, no longer recruiting to completed.
- 23 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Aug 2018.